NCT07018076Recruiting
Candidate Clinical Correlate of Prognostic Outcome for TB Study
Source: ClinicalTrials.gov · Last updated 20 Jul 2026
Brief summary (registry, in English)
As part of the ongoing efforts within the Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) study, the Candidate Clinical Correlate as Prognostic Outcome for TB (C3PO) study serves as a supplement aimed at evaluating predictors and novel biomarkers of recurrent TB among TB survivors. Current tools for predicting TB recurrence risk are suboptimal, limiting the ability to assess new TB treatment regimens effectively. Identifying accurate sputum- or blood-based biomarkers for recurrence risk could significantly improve the efficiency and informativeness of Phase 2 and 3 clinical trials.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 750 (estimated)
- First submitted
- 4 Jun 2025
- Start date
- 25 Nov 2025
- Primary completion date
- 31 May 2027
- Lead sponsor
- University of California, San Francisco
- Diseases
- Tuberculosis
- NCT number
- NCT07018076
What you commit to
- Study type: Observational
- Planned participants: 750
- From 25 Nov 2025 to the primary completion date, 31 May 2027
- 3 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- completed treatment for drug-susceptible tuberculosis \>14 days prior to screening/enrollment;
Other illness
- routinely taking any medication with anti-mycobacterial activity (including fluoroquinolones) for any reason not related to tuberculosis treatment within the last 14 days;
Other
- unwilling to provide informed consent or return for study follow-up visits.
Who the study is looking for
- . individuals age ≥ 12 years;
- . have completed treatment for drug-susceptible tuberculosis with the standard 6-month regimen of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE).
Age in the registry: 12 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kisenyi Health Center Coordinator of this site? Confirm its status | Kampala | Uganda | Recruiting |
| Mulago Outpatient Department Coordinator of this site? Confirm its status | Kampala | Uganda | Recruiting |
| Hanoi Lung Hospital, Outpatient departments Coordinator of this site? Confirm its status | Hanoi | Vietnam | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.